A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults

BACKGROUND: Promising clinical data and significant antigen-sparing have been demonstrated for a pandemic H5N1 influenza split-virion vaccine adjuvanted with AS03(A), an α-tocopherol-containing oil-in-water emulsion-based Adjuvant System. Although studies using this formulation have been reported, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Hideaki, Ikematsu, Hideyuki, Tenjinbaru, Kazuyoshi, Maeda, Atsushi, Dramé, Mamadou, Roman, François P
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004909/
https://www.ncbi.nlm.nih.gov/pubmed/21108818
http://dx.doi.org/10.1186/1471-2334-10-338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004909/
https://www.ncbi.nlm.nih.gov/pubmed/21108818
http://dx.doi.org/10.1186/1471-2334-10-338

Ejemplares similares